SomaCeuticals

SomaCeuticals was a Texas subsidiary of AngioSoma focused on commercializing wellness, nutraceutical, and certain healthcare products under the SomaCeuticals brand. Public disclosures tied the business to AngioSoma's broader efforts around Liprostin, a liposomal prostaglandin E1 program for peripheral artery disease, and to an exclusive license agreement aimed at a multiple sclerosis treatment opportunity. The brand was also associated with supplement and wellness marketing activities rather than a clearly independent, fully staffed drug-development organization. Based on the available public record, SomaCeuticals appears to have functioned primarily as a branded subsidiary/business unit rather than a standalone operating biotech with a well-defined current pipeline. Recent evidence of active operations is limited, so the entity appears inactive or dormant as of 2026.